Phase II trial on the use of Dextran 70 or starch for supportive therapy in Kenyan children with severe malaria

被引:20
|
作者
Akech, Samuel O. [1 ]
Jemutai, Julie [1 ]
Timbwa, Molline [1 ]
Kivaya, Esther [1 ]
Boga, Mwanamvua [1 ]
Fegan, Greg [1 ,2 ]
Maitland, Kathryn [1 ,3 ,4 ]
机构
[1] Ctr Geog Med Res Coast, KEMRI Wellcome Trust Res Programme, Kilifi, Kenya
[2] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England
[3] Univ London Imperial Coll Sci Technol & Med, Dept Paediat, London, England
[4] Univ London Imperial Coll Sci Technol & Med, Global Hlth Programme, London, England
基金
英国惠康基金;
关键词
clinical trials; child; malaria; acidosis; colloids; Dextran; starch; CLINICAL-PRACTICE PARAMETERS; HYDROXYETHYL STARCH; HEMODYNAMIC SUPPORT; VOLUME EXPANSION; RENAL-FUNCTION; ALBUMIN; MANAGEMENT; RESUSCITATION; INDICATORS; ACIDOSIS;
D O I
10.1097/CCM.0b013e3181e81165
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: A previous meta-analysis has shown a consistent survival benefit in children with severe malaria receiving human albumin solution compared to other resuscitation fluids. Human albumin solution is expensive and not readily available in Africa. We examined the safety and efficacy of the fluid resuscitation with two synthetic colloids, Dextran 70 and hydroxyethyl starch, to inform future trial design. Design: An open-label randomized, controlled, phase II safety and efficacy trial. Setting: High-dependency unit, Kilifi District Hospital, Kenya. Patients: Children aged >6 months with severe falciparum malaria and acidosis (base deficit >8 mmol). Interventions: Boluses (20-40 mL/kg) of 6% Dextran 70 and 6% hydroxyethyl starch (130/0.4). Measurements and Main Results: Primary end point: resolution of shock over 8 hrs. Secondary end points include resolution of acidosis, in-hospital mortality, and adverse events (allergic reactions, pulmonary edema, and neurologic sequelae). A total of 79 children were enrolled: 39 received Dextran 70 and 40 received hydroxyethyl starch. No significant difference was observed in Dextran 70 and hydroxyethyl starch groups for shock resolution at 8 hrs: 23/37 (62%) and 25/39 (64%), respectively (p = .99). Acidosis resolution and respiratory distress were marginally superior in the hydroxyethyl starch group: 3/39 (8%) remained acidotic at 8 hrs versus 10/37 (27%) in the Dextran 70 arm (p = .05). There were four deaths (5%): two per arm, including three deaths in the coma subgroup (3/39, 8%). No other new adverse event was reported. Conclusions: Correction of shock by volume expansion with either Dextran 70 or hydroxyethyl starch in children with severe malaria acidosis is safe with low mortality, including the highest risk cases admitted in coma. Both solutions present an attractive and practical option for consideration in future volume resuscitation trials in severe malaria. (Crit Care Med 2010; 38: 1630-1636)
引用
收藏
页码:1630 / 1636
页数:7
相关论文
共 50 条
  • [41] Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial
    Gregoire, Celine
    Layios, Nathalie
    Lambermont, Bernard
    Lechanteur, Chantal
    Briquet, Alexandra
    Bettonville, Virginie
    Baudoux, Etienne
    Thys, Marie
    Dardenne, Nadia
    Misset, Benoit
    Beguin, Yves
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [42] HYPERFRACTIONATED RADIATION-THERAPY (72 GY) FOR CHILDREN WITH BRAIN-STEM GLIOMAS - A CHILDRENS CANCER GROUP PHASE I/II TRIAL
    PACKER, RJ
    BOYETT, JM
    ZIMMERMAN, RA
    RORKE, LB
    KAPLAN, AM
    ALBRIGHT, AL
    SELCH, MT
    FINLAY, JL
    HAMMOND, GD
    WARA, WM
    CANCER, 1993, 72 (04) : 1414 - 1421
  • [43] Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial
    Vanderijst, Laetitia
    Hever, Felix
    Buot, Anne
    Daure, Charles
    Benoit, Janaina
    Hanak, Catherine
    Veeser, Johannes
    Morgieve, Margot
    Campanella, Salvatore
    Kornreich, Charles
    Mallet, Luc
    Leys, Christophe
    Noel, Xavier
    BMC PSYCHIATRY, 2024, 24 (01)
  • [44] Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial
    Laetitia Vanderijst
    Felix Hever
    Anne Buot
    Charles Dauré
    Janaïna Benoit
    Catherine Hanak
    Johannes Veeser
    Margot Morgiève
    Salvatore Campanella
    Charles Kornreich
    Luc Mallet
    Christophe Leys
    Xavier Noël
    BMC Psychiatry, 24
  • [45] Clinical Outcomes from a Phase I/II Gene Therapy Trial for Patientsaffected by Severe Transfusion Dependent Beta-Thalassemia: Two Years Follow Up
    Scaramuzza, S.
    Marktel, S.
    Giglio, F.
    Cicalese, Mp.
    Lidonnici, Mr.
    Rossi, C.
    Calbi, V.
    Masera, N.
    D'Angelo, E.
    Mirra, N.
    Origa, R.
    Tartaglione, I.
    Perrotta, S.
    Viarengo, G.
    Santoleri, L.
    Milani, R.
    Gattillo, S.
    Calabria, A.
    Montini, E.
    Graziadei, G.
    Naldini, L.
    Cappellini, Md.
    Aiuti, A.
    Ciceri, F.
    Ferrari, G.
    MOLECULAR THERAPY, 2020, 28 (04) : 169 - 169
  • [46] Phase II Clinical Trial of Gene Therapy for Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA-SCID) Using γ-Retroviral Vector
    Shaw, Kit L.
    Garabedian, Elizabeth
    Sokolic, Rob
    Barman, Provaboti
    Davila, Alejandra
    Silvin, Christopher
    de Oliveira, Satiro
    Shah, Ami J.
    Terrazas, Dayna
    Carbonaro, Denise
    Geiger, Sabine
    Mishra, Suparna
    Cooper, Aaron
    Smogorzewska, Monika
    Jagadeesh, Jayashree
    Hershfield, Michael S.
    Wayne, Alan
    Crooks, Gay M.
    Moore, Theodore
    Candotti, Fabio
    Kohn, Donald B.
    MOLECULAR THERAPY, 2015, 23 : S13 - S14
  • [47] Dasiglucagon, a Ready-To-Use Glucagon Analog, For Rapid And Effective Treatment of Severe Hypoglycemia: a Phase 3, Randomized Controlled Trial in Children With Type 1 Diabetes
    Battelino, Tadej
    Tehranchi, Ramin
    Bailey, Timothy
    Dovc, Klemen
    Melgaard, Anita
    Stone, Jenine Y.
    Woerner, Stephanie
    von dem Berg, Thekla
    DiMeglio, Linda A.
    Kendall, David
    Danne, Thomas
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 116 : 16 - 17
  • [48] DASIGLUCAGON, A READY-TO-USE GLUCAGON ANALOG, FOR FAST AND EFFECTIVE TREATMENT OF SEVERE HYPOGLYCEMIA: A PHASE 3, RANDOMIZED CONTROLLED TRIAL IN CHILDREN WITH TYPE 1 DIABETES
    Battelino, T.
    Tehranchi, R.
    Bailey, T.
    Dovc, K.
    Melgaard, A.
    Stone, J.
    Woerner, S.
    Berge, T. Von Dem
    Dimeglio, L.
    Danne, T.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A162 - A163
  • [49] Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial
    Ali, Shaukat
    Shalim, Elisha
    Farhan, Farah
    Anjum, Fatima
    Ali, Ayesha
    Uddin, Syed Muneeb
    Shahab, Faisal
    Haider, Mustafa
    Ahmed, Iqra
    Ali, Mir Rashid
    Khan, Sadaf
    Rao, Sadia
    Guriro, Kabeer
    Elahi, Saud
    Ali, Muhammad
    Mushtaq, Tehreem
    Sayeed, Muneeba Ahsan
    Muhaymin, Sheikh Muhammad
    Luxmi, Shoba
    Saifullah
    Qureshi, Saeed
    TRIALS, 2022, 23 (01)
  • [50] Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial
    Shaukat Ali
    Elisha Shalim
    Farah Farhan
    Fatima Anjum
    Ayesha Ali
    Syed Muneeb Uddin
    Faisal Shahab
    Mustafa Haider
    Iqra Ahmed
    Mir Rashid Ali
    Sadaf Khan
    Sadia Rao
    Kabeer Guriro
    Saud Elahi
    Muhammad Ali
    Tehreem Mushtaq
    Muneeba Ahsan Sayeed
    Sheikh Muhammad Muhaymin
    Shoba Luxmi
    Saeed Saifullah
    Trials, 23